PE20091029A1 - Anticuerpos anti-alfa 5 beta 1 - Google Patents
Anticuerpos anti-alfa 5 beta 1Info
- Publication number
- PE20091029A1 PE20091029A1 PE2008001669A PE2008001669A PE20091029A1 PE 20091029 A1 PE20091029 A1 PE 20091029A1 PE 2008001669 A PE2008001669 A PE 2008001669A PE 2008001669 A PE2008001669 A PE 2008001669A PE 20091029 A1 PE20091029 A1 PE 20091029A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- sequence
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
REFERIDA A UN ANTICUERPO ANTI-ALFA 5 BETA 1 QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS DE DOMINIO VARIABLE QUE COMPRENDE: (1) UN LHVR1 QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS KASQ-N/S-VGSDVA (SEQ ID Nº10), (2) UN LHVR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS STSYRYS (SEQ ID Nº11) Y (3) UN LHVR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS QQY-N/S-SYPFT (SEQ ID Nº12); Y UNA SECUENCIA DE DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDE: (1) UN HHVR1 QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS GYTF-T/S-DYYLY (SEQ ID Nº13), (2) UN HHVR2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS GISPS-N/S-GGTTF-N/A-D-N/A-FE-N/G (SEQ ID Nº14) Y (3) UN HHVR3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DAYGDWYFDV (SEQ ID Nº15), DONDE EL ANTICUERPO SE SELCCIONA DE Fab, Fab', F(ab)'2, Fv (ScFv) DE CADENA UNICA, UN FRAGMENTO DE Fv, UN DIACUERPO Y UN ANTICUERPO LINEAL. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL ANTICUERPO Y UN ANTAGONISTA DEL VEGF. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DEL CANCER, INHIBICION DE LA ANGIOGENESIS Y/O PERMEABILIDAD VASCULAR
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97547107P | 2007-09-26 | 2007-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091029A1 true PE20091029A1 (es) | 2009-08-19 |
Family
ID=40329277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008001669A PE20091029A1 (es) | 2007-09-26 | 2008-09-25 | Anticuerpos anti-alfa 5 beta 1 |
Country Status (22)
Country | Link |
---|---|
US (3) | US7973138B2 (es) |
EP (1) | EP2200700B1 (es) |
JP (1) | JP2011501656A (es) |
KR (1) | KR20100065162A (es) |
CN (1) | CN101888878B (es) |
AR (1) | AR066170A1 (es) |
AU (1) | AU2008304452B2 (es) |
BR (1) | BRPI0816049A2 (es) |
CA (1) | CA2698609A1 (es) |
CL (1) | CL2008002856A1 (es) |
CO (1) | CO6260094A2 (es) |
DK (1) | DK2200700T3 (es) |
HR (1) | HRP20160308T1 (es) |
HU (1) | HUE027911T2 (es) |
MX (1) | MX2010003325A (es) |
MY (1) | MY151191A (es) |
NZ (1) | NZ584838A (es) |
PE (1) | PE20091029A1 (es) |
RU (1) | RU2490277C2 (es) |
SI (1) | SI2200700T1 (es) |
TW (1) | TWI547503B (es) |
WO (1) | WO2009042746A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
CA2753988C (en) * | 2009-03-25 | 2017-04-25 | Genentech, Inc. | Novel anti-.alpha.5.beta. integrin antibodies and uses thereof |
CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
JP5383905B2 (ja) | 2009-05-08 | 2014-01-08 | ジェネンテック, インコーポレイテッド | ヒト化抗egfl7抗体とその使用方法 |
US8956600B2 (en) | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
US20130058926A1 (en) * | 2011-08-30 | 2013-03-07 | Shiseido Company, Ltd. | Method for alleviating and/or preventing skin reddening |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
US9494597B2 (en) * | 2012-04-02 | 2016-11-15 | Ab Biosciences, Inc. | Human control antibodies and uses therefor |
EP3553089A1 (en) | 2012-05-10 | 2019-10-16 | Bioatla, LLC | Multi-specific monoclonal antibodies |
ES2682345T3 (es) | 2012-09-27 | 2018-09-20 | Biocare Medical, Llc | Sistemas y procedimientos de anticuerpos antiuroplaquina II |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
CN104994874B (zh) | 2012-12-26 | 2017-04-12 | 安科协同公司 | 抗整联蛋白β1抗体组合物及其使用方法 |
EP2948472B1 (en) | 2013-01-23 | 2019-05-22 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
WO2014122144A1 (en) * | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
JP6445467B2 (ja) | 2013-02-28 | 2019-01-09 | バイオケア メディカル, エルエルシー | 抗p40抗体システムおよび方法 |
ES2765423T3 (es) | 2013-10-03 | 2020-06-09 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti-SOX10 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
CN108693004B (zh) * | 2018-05-24 | 2020-08-04 | 中国农业科学院农业质量标准与检测技术研究所 | 一种检测菜籽粕中是否掺杂抗生素滤渣的方法 |
KR20220047536A (ko) * | 2019-04-01 | 2022-04-18 | 레이크파르마, 인코퍼레이티드 | 면역반응의 조절 및 질병의 치료를 위한 btla-결합(cd272) 항체 |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
CN114688461A (zh) * | 2020-12-31 | 2022-07-01 | 青岛海尔施特劳斯水设备有限公司 | 一种漏水检测方法及*** |
CN113133431A (zh) * | 2021-02-25 | 2021-07-20 | 中南大学 | 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用 |
CN114073996B (zh) * | 2021-11-24 | 2023-04-14 | 中山大学 | 一种嵌套式微井阵列芯片及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540933A (en) | 1985-05-31 | 1996-07-30 | La Jolla Cancer Research Foundation | Isolation and use of fibronectin receptor |
EP0330506A3 (en) | 1988-02-26 | 1990-06-20 | Dana Farber Cancer Institute | Vla proteins |
US20020146410A1 (en) | 1992-05-22 | 2002-10-10 | Helmut Eckert | Monoclonal antibodies and their use |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5627263A (en) | 1993-11-24 | 1997-05-06 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
PT719859E (pt) | 1994-12-20 | 2003-11-28 | Merck Patent Gmbh | Anticorpo monoclonal anti-alfa v-integrina |
ID27810A (id) | 1998-01-23 | 2001-04-26 | Merck Patent Gmbh | Antibodi menoclonal anti v-integrin dan kegunaan untuk mencegah penambahan v 6-integrin untuk fibronectin |
US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
PT1075277E (pt) | 1998-05-08 | 2009-05-08 | Univ California | Métodos para detectar e inibir a angiogénese |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
GB9909392D0 (en) | 1999-04-24 | 1999-06-23 | Imp Cancer Res Tech | Treatment, imaging and diagnosis of disease |
US20040009494A1 (en) | 1999-08-11 | 2004-01-15 | Richard Murray | Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators |
US20020019330A1 (en) | 1999-08-11 | 2002-02-14 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20020015970A1 (en) | 1999-08-11 | 2002-02-07 | Richard Murray | Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators |
US20030152926A1 (en) | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
WO2001011086A2 (en) | 1999-08-11 | 2001-02-15 | Eos Biotechnology, Inc. | Methods of screening for angiogenesis modulators |
US20040259152A1 (en) | 2000-02-22 | 2004-12-23 | Richard Murray | Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases |
EP1418943A1 (en) | 2001-02-14 | 2004-05-19 | Protein Design Labs, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス, インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
AU2002314901A1 (en) | 2001-06-04 | 2002-12-16 | Eos Biotechnology, Inc. | Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer |
US7189507B2 (en) | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
CA2451465A1 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20040076955A1 (en) | 2001-07-03 | 2004-04-22 | Eos Biotechnology, Inc. | Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer |
US20040033495A1 (en) | 2001-08-03 | 2004-02-19 | Eos Biotechnology, Inc. | Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030124579A1 (en) | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20070042360A1 (en) | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20030232350A1 (en) | 2001-11-13 | 2003-12-18 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
WO2004001384A2 (en) | 2002-06-25 | 2003-12-31 | The Regents Of The University Of California | Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival |
EP1539247A4 (en) | 2002-07-16 | 2007-08-29 | Univ New Jersey Med | ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH |
US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
ES2387985T3 (es) * | 2002-11-26 | 2012-10-05 | Abbott Biotherapeutics Corp. | Anticuerpos quiméricos y humanizados de integrina alfa 5 beta 1 que modulan la angiogénesis |
US7276589B2 (en) * | 2002-11-26 | 2007-10-02 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
WO2004089988A2 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
NZ549893A (en) * | 2004-03-24 | 2010-05-28 | Facet Biotech Corp | Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit cancer cell proliferation |
US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
CA2591148A1 (en) | 2004-12-09 | 2006-06-15 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
US20090137601A1 (en) | 2005-11-23 | 2009-05-28 | Astrazeneca Ab | L-Phenylalanine Derivatives |
US20090111828A1 (en) | 2005-11-23 | 2009-04-30 | Astrazeneca Ab | L-alanine derivatives |
US20090203663A1 (en) | 2006-02-09 | 2009-08-13 | Astrazeneca Ab | Chemical compounds |
NZ615012A (en) * | 2006-03-21 | 2015-11-27 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
EP2032605A2 (en) | 2006-05-24 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
AR066170A1 (es) | 2007-09-26 | 2009-07-29 | Genentech Inc | Anti integrina alfa 5 beta 1 |
KR20100115360A (ko) | 2008-02-05 | 2010-10-27 | 브리스톨-마이어스 스큅 컴퍼니 | 알파 5-베타 1 항체 및 이의 용도 |
-
2008
- 2008-09-25 AR ARP080104170A patent/AR066170A1/es unknown
- 2008-09-25 SI SI200831589T patent/SI2200700T1/sl unknown
- 2008-09-25 TW TW097136935A patent/TWI547503B/zh not_active IP Right Cessation
- 2008-09-25 AU AU2008304452A patent/AU2008304452B2/en not_active Ceased
- 2008-09-25 BR BRPI0816049A patent/BRPI0816049A2/pt not_active IP Right Cessation
- 2008-09-25 CL CL2008002856A patent/CL2008002856A1/es unknown
- 2008-09-25 KR KR1020107006513A patent/KR20100065162A/ko active IP Right Grant
- 2008-09-25 NZ NZ584838A patent/NZ584838A/xx not_active IP Right Cessation
- 2008-09-25 HU HUE08834260A patent/HUE027911T2/en unknown
- 2008-09-25 DK DK08834260.5T patent/DK2200700T3/en active
- 2008-09-25 EP EP08834260.5A patent/EP2200700B1/en active Active
- 2008-09-25 US US12/237,640 patent/US7973138B2/en not_active Expired - Fee Related
- 2008-09-25 CA CA2698609A patent/CA2698609A1/en not_active Abandoned
- 2008-09-25 MY MYPI20101284 patent/MY151191A/en unknown
- 2008-09-25 RU RU2010116184/10A patent/RU2490277C2/ru not_active IP Right Cessation
- 2008-09-25 JP JP2010527128A patent/JP2011501656A/ja active Pending
- 2008-09-25 MX MX2010003325A patent/MX2010003325A/es active IP Right Grant
- 2008-09-25 CN CN200880117702.0A patent/CN101888878B/zh not_active Expired - Fee Related
- 2008-09-25 WO PCT/US2008/077622 patent/WO2009042746A1/en active Application Filing
- 2008-09-25 PE PE2008001669A patent/PE20091029A1/es not_active Application Discontinuation
-
2010
- 2010-03-19 CO CO10033130A patent/CO6260094A2/es active IP Right Grant
-
2011
- 2011-05-20 US US13/112,839 patent/US8840887B2/en not_active Expired - Fee Related
- 2011-05-20 US US13/112,833 patent/US9284376B2/en not_active Expired - Fee Related
-
2016
- 2016-03-23 HR HRP20160308TT patent/HRP20160308T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP2200700A1 (en) | 2010-06-30 |
AU2008304452A1 (en) | 2009-04-02 |
MX2010003325A (es) | 2010-04-09 |
AU2008304452B2 (en) | 2014-01-16 |
CO6260094A2 (es) | 2011-03-22 |
BRPI0816049A2 (pt) | 2019-09-24 |
SI2200700T1 (sl) | 2016-04-29 |
AR066170A1 (es) | 2009-07-29 |
US8840887B2 (en) | 2014-09-23 |
RU2010116184A (ru) | 2011-11-10 |
CL2008002856A1 (es) | 2009-01-16 |
TWI547503B (zh) | 2016-09-01 |
US20090098112A1 (en) | 2009-04-16 |
WO2009042746A1 (en) | 2009-04-02 |
RU2490277C2 (ru) | 2013-08-20 |
NZ584838A (en) | 2012-08-31 |
JP2011501656A (ja) | 2011-01-13 |
TW200924794A (en) | 2009-06-16 |
MY151191A (en) | 2014-04-30 |
CA2698609A1 (en) | 2009-04-02 |
CN101888878A (zh) | 2010-11-17 |
HRP20160308T1 (hr) | 2016-04-22 |
HUE027911T2 (en) | 2016-11-28 |
US7973138B2 (en) | 2011-07-05 |
US9284376B2 (en) | 2016-03-15 |
CN101888878B (zh) | 2014-05-21 |
EP2200700B1 (en) | 2016-01-13 |
US20120156129A1 (en) | 2012-06-21 |
KR20100065162A (ko) | 2010-06-15 |
US20120148572A1 (en) | 2012-06-14 |
DK2200700T3 (en) | 2016-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20091029A1 (es) | Anticuerpos anti-alfa 5 beta 1 | |
MX358013B (es) | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. | |
PE20090359A1 (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas | |
PE20090239A1 (es) | ANTAGONISTAS CRIg | |
RS53270B (en) | MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEINS AND THEIR USE | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
CR20120127A (es) | Anticuerpos monoclonales | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
RS54624B1 (en) | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 | |
RS53760B1 (en) | HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES | |
RS54113B1 (en) | COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN | |
ES2683847T3 (es) | Inmunoglobulina citotóxica | |
UA109658C2 (xx) | Антитіло проти cgrp | |
RS53291B (en) | BETA 1-42 SPECIFIC MONOCLONIC ANTIBODIES WITH THERAPEUTIC PROPERTIES | |
RS54424B1 (en) | HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES | |
PE20141398A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
RS53906B1 (en) | ANTI MIF ANTITELA | |
ES2668645T3 (es) | Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B | |
DE602006013029D1 (de) | Anti-egfr-antikörper | |
BRPI0818437A2 (pt) | Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma | |
GT200900167A (es) | Anticuerpos humanos contra el ligando 4 de tipo delta humano. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |